ArticlemedRxiv : the preprint server for health sciences2025
Machine Learning-Based Identification of Blood Biomarkers that Distinguish Precachectic and Cachectic Patients with Pancreatic Ductal Adenocarcinoma.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
5 authors.
Funding
Abstract
Background: Identification of minimally invasive biomarkers of different stages of cachexia (Ca), and precachexia (PCa) in particular, might help clinicians in treating patients with pancreatic ductal adenocarcinoma (PDAC) at high risk of progressing to a more severe cachectic stage. In this work, we developed a machine-learning (ML) model optimized to blood biomarkers data that identifies precachectic and cachectic patients. Methods: Blood and clinical data was collected from treatment-naïve patients with PDAC through the Florida Pancreas Collaborative (FPC), a multi-institutional cohort study and biobanking initiative. Blood was processed into serum and assayed for a total of 35 candidate biomarkers. Participants were classified as having noncachexia (NCa), precachexia, or cachexia according to modified criteria by Vigano and colleagues which consider unintentional weight loss and biochemical data. Using these data, we designed ML algorithms to: (i) pre-select predictive blood biomarker candidates using a combination of mutual information method together with the leave-one-feature-out (LOFO) feature importance approach; (ii) identify the minimal combination of predictive biomarkers using the forward feature selection method; (iii) determine the optimal classification hyperparameters for the support vector machine using a cross-validation technique; and (iv) adjust the decision-boundary threshold for imbalanced data using the Matthews correlation coefficient. Three ML-based binary predictors were designed to determine patients' cachexia status: NCa vs. Ca; PCa vs. Ca; and PCa vs. NCa. Results: The biomarker levels from 184 patients (28 NCa, 53 PCa, and 103 Ca) were used in this study. The NCa vs. Ca predictor identified a set of 6 biomarkers and yielded area under the curve (AUC) of 0.835. The PCa vs. Ca predictor identified a set of 6 biomarkers and yielded AUC of 0.810. The PCa vs. NCa predictor identified a set of 5 biomarkers and yielded AUC of 0.771. Conclusions: The developed ML models that use blood biomarker data provided effective predictions of patient's cachexia stage that can help clinicians to diagnose PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.